You are here: Industry Insights > GSK

News List

Vir Biotechnology and GSK start phase 2/3 study of COVID-19 antibody treatment worldpharmanews
September 01, 2020
Vir Biotechnology, Inc. and GlaxoSmithKline plc announced that the first patient was dosed last week in a phase 2/3 study with VIR-7831 (also known as GSK4182136), a fully human anti-SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus-2) ...
First patients dosed in GSK’s Phase III meningitis vaccine trial europeanpharmaceuticalreview
August 28, 2020
The trial will assess the safety, tolerability and immunogenicity of the five-in-one MenABCWY vaccine in participants aged 10 to 25.
GSK bags EU approval for Blenrep pharmatimes
August 27, 2020
Hot on the heels of US approval GlaxoSmithKline has now also bagged a nod in Europe for Blenrep (belantamab mafodotin-blmf) as a treatment for patients with relapsed for refractory multiple myeloma (MM).
First trial participant gets GSK's 5-in-1 meningitis jab pharmatimes
August 21, 2020
Patient dosing has begun in a Phase III clinical programme investigating GlaxoSmithKline's 5-in-1 meningitis (MenABCWY) vaccine candidate compared to licensed meningococcal vaccines, Bexsero and Menveo.
GSK gets USFDA approval for BLENREP to treat relapsed or refractory multiple myeloma expresspharma
August 07, 2020
BLENREP is the fifth major medicine approval for GSK in 2020.
GSK Shipping Influenza Vaccine Doses for 2020-21 Season for US Market americanpharmaceuticalreview
August 05, 2020
GSK has started shipping its quadrivalent influenza vaccines to US healthcare providers and pharmacies for the 2020-21 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration's (FDA) Center for...
Sanofi and GSK Selected for Operation Warp Speed contractpharma
August 04, 2020
To supply U.S. government with 100 million doses of COVID-19 vaccine in $2.1 billion deal.
US commits $2.1bn for 100 million Sanofi-GSK Covid-19 vaccine doses pharmaceutical-technology
August 03, 2020
The US Government has committed to providing up to $2.1bn to Sanofi and GlaxoSmithKline (GSK) for development, manufacturing, scale-up and delivery of an initial 100 million doses of the companies’ Covid-19 vaccine candidate.
Sanofi, GSK to supply 100 mn doses of COVID-19 vaccine to US, in talks with EU for 300 mn doses expresspharma
August 03, 2020
The deal is worth $2.1 billion and involves the supply of vaccines for 50 million people, with the option to buy another 500 million doses.
GSK sees dip in second-quarter sales pharmatimes
July 31, 2020
GlaxoSmithKline has reported group sales of £7.6 billion for the second quarter of 2020, marking a slip of 2% from a year ago, reflecting expected disruption from COVID-19.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 40 41 Next page